Skip to main content

Table 1 Effective doses at 10, 50 and 90% effect levels of QLT0267 in human breast tumour cell lines

From: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Cell line

Drug concentration range (μM)

ED10 (μM)

ED50 (μM)

ED90 (μM)

MDA MB 435/LCC6

2.0 to 256.0

2.05

17.2

143.6

MDA MB 435/LCC6her2/neu

2.0 to 256.0

1.66

12.2

90.4

MDA MB 468

1.0 to 133.3

0.91

25.6

718.7

MCF-7

1.0 to 133.3

1.15

9.8

83.3

KPL-4

2.0 to 256.0

0.31

12.1

473.0

BT-474

2.0 to 256.0

29.8

70.9

168.2

SKBR-3

2.0 to 256.0

28.8

55.8

108.2

  1. Effective doses (ED) values were calculated with Calcusyn software using the median effect principle defined by Chou and Talalay [26].
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us